2 active not recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 2 |
Follow DFMO: new trials by email Literature Review of DFMO trials Research Report on DFMO
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TArgeting Type 1 Diabetes Using POLyamines (TADPOL) DFMO, Placebo - Type 1 Diabetes | Phase 2 | Active not recruiting | Emily K. Sims | 74 | 2023-03-14 | 2026-08-21 |
| Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma Eflornithine - Neuroblastoma | Phase 2 | Active not recruiting | Giselle Sholler | 131 | 2020-09-25 | 2026-09-03 |
Diabetes Mellitus, Type 1 (1) · Neuroblastoma (1)
Emily K. Sims (1) · Giselle Sholler (1)
United States (2) · Canada (1)
Emily K Sims, MD,MS (1) · Giselle Sholler, MD (1)
PMID 10024506, PMID 10433086, PMID 10605821, PMID 10852253, PMID 11208527, PMID 11564949, PMID 11815483, PMID 12972423, PMID 15972654, PMID 16011702, PMID 16714282, PMID 17214730, PMID 1730582, PMID 17524725, PMID 18176934, PMID 18360702, PMID 19188144, PMID 19763038, PMID 19968980, PMID 19997760, PMID 20127992, PMID 20405312, PMID 20501948, PMID 20956533, PMID 21147316, PMID 21389784, PMID 22442300, PMID 23250488, PMID 26397425, PMID 2891995, PMID 3093066, PMID 3105526, PMID 3128541, PMID 32391579, PMID 34214479, PMID 431333, PMID 6422008, PMID 6781187, PMID 7895500, PMID 8262968, PMID 8295175, PMID 8356088, PMID 8408643, PMID 9719479